The kidney cancer therapeutics & diagnostics market will show a rapid growth due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.

  • According to the GLOBOCAN, the incidence of Kidney cancer is 4.5 per 100,000 in 2018, worldwide. The 5 major countries contributing to the global cancer cases are China, the United States, Russia, Germany, and Japan. These countries are found to have the highest cases of kidney cancer worldwide.
  • The increasing kidney cancer cases globally is expected to increase the demand for diagnostic methods for early-stage treatment worldwide. As per the American Cancer Society’s recent estimates, in 2019, there were about 73,820 new cases of kidney cancer (44,120 in men and 29,700 in women). Kidney and renal pelvis cancer represent 4.2% of all new cancer cases in the United States. It was estimated that there were around 14,770 deaths in 2019, owing to Kidney and renal pelvis cancer.
  • Currently, there are various treatment options available and many drugs are in pipeline too, which is expected to drive the kidney cancer therapeutics and diagnostics market during the forecast period.
  • In addition, rising investments in research by various government bodies and development of novel drugs by pharmaceutical and biotechnology companies are other major contributing factors.



Key Market Trends

Renal Cancer Carcinoma is Expected to be the Largest Growing Segment in the Kidney Cancer Therapeutics & Diagnostics Market

  • Renal cell cancer is the most common type of cancer which affects more than 30,000 people annually on an average and 40% of them die due to complications from this cancer. Therefore different types of therapies are being available and some are being evaluated in clinical trials.
  • There are also other factors that are driving the market that includes growing awareness among people about cancer, the increased diagnostic rates, rising geriatric population, and rising incidence of renal cancer.



North America is found to be Leading the Kidney Cancer Therapeutics & Diagnostics Market

North America dominates the global kidney cancer therapeutics and diagnostics market. The major factor driving the growth is the increasing number of kidney cancer cases. As per the GLOBOCAN 2018 statistics, estimated number of kidney cancer were 60,336 in the United States. Other factors, such as increased R&D expenditure of pharmaceutical companies and increasing incidences of aging population, are expected to lead to the growth of the market in the forecast period.

However, the region of Asia-Pacific is expected to be the fastest growing market during the forecast period. Rising patient base suffering from renal cancer, growing patient awareness and lower costs of drug production are expected to drive the growth of this market.

Competitive Landscape

There has been a presence of a considerable number of companies that are significantly contributing to the market growth. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client’s requirements
  • 3 months of analyst support